Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Cell Therapy Human Raw Materials Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 16.79 Billion as Personalized Medicine Drives 18.44% CAGR

globenewswire.com
TMO Thermo Fisher Scientific is listed as a leading player in the cell therapy human raw materials market, which is projected to grow significantly. The article does not provide specific sentiment towards the company's performance or outlook. MRK Merck KGaA is identified as a key player in the cell therapy human raw materials market, which is expected to experience substantial growth. The article does not offer specific sentiment regarding Merck KGaA's performance or future prospects. CRL Charles River Laboratories is mentioned as a leading company in the cell therapy human raw materials market. The article highlights the market's growth potential but does not provide specific sentiment or performance details for Charles River Laboratories. DHR Danaher is listed among the leading players in the cell therapy human raw materials market. The article forecasts significant market growth but does not offer specific sentiment or performance analysis for Danaher.

Global Cell Therapy Human Raw Materials Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 16.79 Billion as Personalized Medicine Drives 18.44% CAGR Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report by Product, End Use, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global cell therapy human raw materials market was valued at USD 4.37 billion in 2025 and is projected to reach USD 16.79 billion by 2033. The market is expected to expand at a compound annual growth rate of 18.44% from 2026 to 2033, supported by increasing demand for high-quality materials used in cell therapy research, development, and commercial manufacturing.

Market growth is being driven by the rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders. Expanding demand for regenerative medicine and personalized therapies is also increasing the need for reliable cell culture media, sera, supplements, reagents, buffers, and related raw materials. In addition, growing research and development activity, higher investment in advanced therapies, and continued expansion of biopharmaceutical manufacturing capacity are expected to strengthen demand throughout the forecast period.

The global cell therapy human raw materials market report provides revenue forecasts and analysis of key trends across major sub-segments from 2021 to 2033. It evaluates the market by product, end use, and region, enabling organizations to assess commercial opportunities, competitive conditions, and potential areas for strategic investment.

Product Outlook (Revenue, USD Billion, 2021-2033)

Cell culture media, sera, supplements, reagents, and buffers are essential to cell therapy development and manufacturing workflows. Demand across these product categories is expected to increase as companies advance clinical pipelines, improve production processes, and prepare therapies for broader commercialization.

End Use Outlook (Revenue, USD Billion, 2021-2033)

Biopharmaceutical and pharmaceutical companies represent a significant source of demand due to expanding cell therapy pipelines and investment in manufacturing capabilities. CROs and CMOs continue to support development, testing, process optimization, and production activities, while academic and research institutions contribute to early-stage innovation and translational research.

Regional Outlook (Revenue, USD Billion, 2021-2033)

The regional analysis examines market performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. It assesses regional revenue potential, research activity, investment patterns, manufacturing expansion, and the evolving presence of cell therapy developers and suppliers.

Key Benefits of the Cell Therapy Human Raw Materials Market Report

Report Coverage

The report is designed for cell therapy developers, raw material suppliers, biopharmaceutical companies, pharmaceutical manufacturers, CROs, CMOs, investors, and research institutions seeking data-driven insight into this rapidly expanding market. Its findings support market entry planning, portfolio development, competitive benchmarking, partnership strategies, and investment decisions through 2033.

Key Attributes:

Key Topics Covered:

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope

1.1.1. Product

1.1.2. End Use

1.2. Regional Scope

1.3. Estimates and Forecast Timeline

1.4. Objective

1.5. Research Methodology

1.6. Information Procurement

1.6.1. Purchased Database

1.6.2. Internal Database

1.6.3. Secondary Sources

1.6.4. Primary Research

1.7. Information or Data Analysis

1.7.1. Data Analysis Models

1.8. Market Formulation & Validation

1.9. Model Details

1.9.1. Commodity Flow Analysis

1.10. List of Secondary Sources

1.11. List of Abbreviations

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Rapid growth of the cell therapy pipeline

3.2.1.2. Expansion of regenerative medicine and personalized medicine

3.2.1.3. Growing prevalence of immune-related disorders

3.2.2. Market Restraint Analysis

3.2.2.1. Ethical concerns related to stem cell research

3.2.2.2. High cost associated with the production and procurement of raw materials

3.3. Industry Analysis Tools

3.3.1. Porter's Five Forces Analysis

3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis

4.2. Cell Culture Media

4.2.1. Cell culture media market estimates and forecasts, 2021-2033 (USD Million)

4.3. Cell Culture Sera

4.3.1. Cell culture sera market estimates and forecasts, 2021-2033 (USD Million)

4.4. Cell Culture Supplements

4.4.1. Cell culture supplements market estimates and forecasts, 2021-2033 (USD Million)

4.4.2. Proteins

4.4.2.1. Proteins market estimates and forecasts, 2021-2033 (USD Million)

4.4.3. Growth Factors

4.4.3.1. Growth factors market estimates and forecasts, 2021-2033 (USD Million)

4.4.4. Nucleotides

4.4.4.1. Nucleotides market estimates and forecasts, 2021-2033 (USD Million)

4.4.5. Other Supplements

4.4.5.1. Other supplements market estimates and forecasts, 2021-2033 (USD Million)

4.5. Reagents & Buffers

4.5.1. Reagents & buffers market estimates and forecasts, 2021-2033 (USD Million)

4.6. Other Raw Materials

4.6.1. Other raw materials market estimates and forecasts, 2021-2033 (USD Million)

Chapter 5. End Use Group Business Analysis

5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis

5.2. Biopharmaceutical & Pharmaceutical Companies

5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021-2033 (USD Million)

5.3. CROs & CMOs

5.3.1. CROs & CMOs market estimates and forecasts, 2021-2033 (USD Million)

5.4. Academic & Research Institutions

5.4.1. Academic & research institutions market estimates and forecasts, 2021-2033 (USD Million)

Chapter 6. Regional Business Analysis

6.1. Cell Therapy Human Raw Materials Share By Region, 2025 & 2033

6.2. North America

6.2.1. North America Cell Therapy Human Raw Materials, 2021-2033 (USD Million)

6.2.2. U.S.

6.2.3. Canada

6.2.4. Mexico

6.3. Europe

6.3.1. Europe Cell Therapy Human Raw Materials, 2021-2033 (USD Million)

6.3.2. UK

6.3.3. Germany

6.3.4. France

6.3.5. Italy

6.3.6. Spain

6.3.7. Denmark

6.3.8. Sweden

6.3.9. Norway

6.4. Asia Pacific

6.4.1. Asia Pacific Cell Therapy Human Raw Materials, 2021-2033 (USD Million)

6.4.2. Japan

6.4.3. China

6.4.4. India

6.4.5. Australia

6.4.6. Thailand

6.4.7. South Korea

6.5. Latin America

6.5.1. Latin America Cell Therapy Human Raw Materials, 2021-2033 (USD Million)

6.5.2. Brazil

6.5.3. Argentina

6.6. MEA

6.6.1. MEA Cell Therapy Human Raw Materials, 2021-2033 (USD Million)

6.6.2. South Africa

6.6.3. Saudi Arabia

6.6.4. UAE

6.6.5. Kuwait

6.7. Country-Level Analysis

6.7.1. Key Country Dynamics

6.7.2. Competitive Scenario

6.7.3. Regulatory Framework

6.7.4. Target Disease Prevalence

6.7.5. Country-Level Cell Therapy Human Raw Materials Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Company Categorization

7.2. Strategy Mapping

7.3. Company Market Position/Share Analysis, 2025

7.4. Company Profiles/Listing

7.4.1. Thermo Fisher Scientific, Inc

7.4.2. Merck KGaA

7.4.3. Actylis

7.4.4. ACROBiosystems

7.4.5. STEMCELL Technologies

7.4.6. Grifols, S.A.

7.4.7. Charles River Laboratories

7.4.8. RoosterBio, Inc.

7.4.9. PromoCell GmbH

7.4.10. Danaher

7.4.11. BioIVT

7.4.12. GeminiBio

7.4.13. Akron Biotech

7.4.14. AllCells

7.4.15. CGT Global

7.5. Company Profile Analysis

7.5.1. Overview

7.5.2. Financial Performance, as applicable

7.5.3. Product Benchmarking

7.5.4. Strategic Initiatives

List of Tables [62]

List of Figures [61]

Companies Featured

The leading players profiled in this Cell Therapy Human Raw Materials market report include:

For more information about this report visit https://www.researchandmarkets.com/r/dbduwy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.